Skip to main content
Equibles
DNA logo

DNA · Ginkgo Bioworks Holdings, Inc. · Webcasts, Transcripts & Audio

Track DNA — free

Use DNA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research DNA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$12.50 -0.33 (-2.57%) At close · Oct 1
Russell 2000 member Rebalance outlook locked
Market Cap
$577.78M
Shares
67.34M
Volume · Oct 1 2.92M Avg daily vol (3M) 1.38M

Ginkgo Bioworks Holdings, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Ginkgo Bioworks Holdings, Inc. (DNA), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▼14.4% $66.40M −$670.13M '22 Q3 22-11-14 ▼33.8% $98.28M −$175.47M '22 Q4 23-01-11 ▼52.1% $80.70M −$204.97M '23 Q1 23-05-10 ▼44.3% $80.57M −$173.31M '23 Q2 23-08-09 ▼16.5% $55.43M −$302.89M '23 Q3 23-11-08 ▼64.6% $34.76M −$211.69M '23 Q4 24-02-29 ▼53% $37.94M −$165.91M '24 Q1 24-05-09 ▼30.2% $56.21M −$217.18M '24 Q2 24-06-30 ▲60.6% $89.05M −$56.40M '24 Q3 24-11-12 ▲26.2% $43.85M −$107.53M '24 Q4 25-02-25 ▲0.8% $38.23M −$90.96M '25 Q1 25-05-06 ▼30.4% $39.13M −$60.30M '25 Q2 25-08-07 ▼56.4% $38.84M −$80.75M '25 Q3 25-11-06 ▲23.1% $53.95M −$80.75M '25 Q4 26-02-26 ▼49.1% $19.47M −$82.59M '26 Q1 26-05-07 LATEST ▼48.5% $20.16M −$46.71M '26 Q2 26-08-05
Earnings call
FY26 · Q2
2026-08-05
Ginkgo Bioworks Holdings, Inc. (DNA) Q2 2026 Earnings Call
Positive tone Nebula lab in Boston NSF-funded university labs announcement Autonomous labs as national imperative
Revenue
$20.16M
▼ 48.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-07
Ginkgo Bioworks Holdings, Inc. (DNA) Q1 2026 Earnings Call Transcript
Positive tone Autonomous labs / Nebula strategy AI, robotics & software investment Financial performance
Revenue
$19.47M
▼ 49.1% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-26
Ginkgo Bioworks Holdings, Inc. (DNA) Q4 2025 Earnings Call Transcript
Positive tone Cell Engineering Revenue Decline Autonomous Labs Strategy Cost Restructuring & Cash Burn
Revenue
$53.95M*
▲ 23.1% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Conference
Investor event
2026-01-15
Ginkgo Bioworks Holdings, Inc. (DNA) January 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY25 · Q3
2025-11-06
Ginkgo Bioworks Holdings, Inc. (DNA) Q3 2025 Earnings Call Transcript
Positive tone Tools business and robotics Biosecurity business AI and biology transformation
Revenue
$38.84M
▼ 56.4% YoY
Diluted EPS
$-1.45
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Ginkgo Bioworks Holdings, Inc. (DNA) Q2 2025 Earnings Call Transcript
Positive tone Cost restructuring and EBITDA breakeven target Biosecurity business and guidance reduction Transition to life science tools business
Revenue
$39.13M
▼ 30.4% YoY
Diluted EPS
$-1.10
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-06
Ginkgo Bioworks Holdings, Inc. (DNA) Q1 2025 Earnings Call Transcript
Positive tone Government and Biosecurity opportunities Cell Engineering revenue growth Cost reduction and path to EBITDA breakeven
Revenue
$38.23M
▲ 0.8% YoY
Diluted EPS
$-1.68
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-25
Ginkgo Bioworks Holdings, Inc. (DNA) Q4 2024 Earnings Call Transcript
Positive tone Cell engineering revenue growth Tools and Data Points offerings Adjusted EBITDA break-even and cost cuts
Revenue
$43.85M*
▲ 26.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-12
Ginkgo Bioworks Holdings, Inc. (DNA) Q3 2024 Earnings Call Transcript
Positive tone Cell engineering revenue / customer mix Cost cutting / path to adjusted EBITDA breakeven AI platform / model offerings
Revenue
$89.05M
▲ 60.6% YoY
Diluted EPS
$-1.08
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-06-30
Ginkgo Bioworks Holdings, Inc. (DNA) Q2 2024 Earnings Call Transcript
Cautious tone Tools and platform democratization Cost reduction and path to EBITDA breakeven Biosecurity business
Revenue
$56.21M
▼ 30.2% YoY
Diluted EPS
$-4.23
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
Ginkgo Bioworks Holdings, Inc. (DNA) Q1 2024 Earnings Call Transcript
Positive tone RAC automation platform and Biofab1 consolidation Downstream value share and guidance withdrawal Path to adjusted EBITDA breakeven
Revenue
$37.94M
▼ 53% YoY
Diluted EPS
$-3.32
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-29
Ginkgo Bioworks Holdings, Inc. (DNA) Q4 2023 Earnings Call Transcript
Positive tone Biopharma customer wins Cell Engineering program growth Biosecurity business
Revenue
$34.76M*
▼ 64.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-08
Ginkgo Bioworks Holdings, Inc. (DNA) Q3 2023 Earnings Call Transcript
Revenue
$55.43M
▼ 16.5% YoY
Diluted EPS
$-6.21
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-09
Ginkgo Bioworks Holdings, Inc. (DNA) Q2 2023 Earnings Call Transcript
Revenue
$80.57M
▼ 44.3% YoY
Diluted EPS
$-3.60
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-10
Ginkgo Bioworks Holdings, Inc. (DNA) Q1 2023 Earnings Call Transcript
Revenue
$80.70M
▼ 52.1% YoY
Diluted EPS
$-4.40
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-01-11
Ginkgo Bioworks Holdings, Inc. (DNA) Q4 2022 Earnings Call Transcript
Revenue
$98.28M*
▼ 33.8% YoY
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-14
Ginkgo Bioworks Holdings, Inc. (DNA) Q3 2022 Earnings Call Transcript
Revenue
$66.40M
▼ 14.4% YoY
Diluted EPS
$-16.40
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-15
Ginkgo Bioworks Holdings, Inc. (DNA) Q2 2022 Earnings Call Transcript
Revenue
$144.62M
▲ 231.4% YoY
Diluted EPS
$-16.40
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-16
Ginkgo Bioworks Holdings, Inc. (DNA) Q1 2022 Earnings Call Transcript
Revenue
$168.41M
▲ 281.9% YoY
Diluted EPS
$-14.80
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-01-12
Ginkgo Bioworks Holdings, Inc. (DNA) Q4 2021 Earnings Call Transcript
Revenue
$148.49M*
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-15
Ginkgo Bioworks Holdings, Inc. (DNA) Q3 2021 Earnings Call Transcript
Revenue
$77.61M
▲ 483.4% YoY
Diluted EPS
$-3.20
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-03-31
Ginkgo Bioworks Holdings, Inc. (DNA) Q1 2021 Earnings Call Transcript
Revenue
$44.10M
Rev · 2q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–22 of 22 webcasts
Key facts CIK 1830214 CUSIP 37611X209 13F (30d) 4 filings 4 filers Visit website Investor relations